Post-Marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the co-Primary Endpoint in Patients (Male) With Diarrhea-Predominant Irritable Bowel Syndrome.
Phase of Trial: Phase IV
Latest Information Update: 14 Oct 2015
At a glance
- Drugs Ramosetron (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 23 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jan 2010 Actual patient number (98) added as reported by ClinicalTrials.gov.
- 25 Jun 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.